Back to Search Start Over

Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study.

Authors :
Costeira R
Lee KA
Murray B
Christiansen C
Castillo-Fernandez J
Ni Lochlainn M
Capdevila Pujol J
Macfarlane H
Kenny LC
Buchan I
Wolf J
Rymer J
Ourselin S
Steves CJ
Spector TD
Newson LR
Bell JT
Source :
PloS one [PLoS One] 2021 Sep 10; Vol. 16 (9), pp. e0257051. Date of Electronic Publication: 2021 Sep 10 (Print Publication: 2021).
Publication Year :
2021

Abstract

It has been widely observed that adult men of all ages are at higher risk of developing serious complications from COVID-19 when compared with women. This study aimed to investigate the association of COVID-19 positivity and severity with estrogen exposure in women, in a population based matched cohort study of female users of the COVID Symptom Study application in the UK. Analyses included 152,637 women for menopausal status, 295,689 women for exogenous estrogen intake in the form of the combined oral contraceptive pill (COCP), and 151,193 menopausal women for hormone replacement therapy (HRT). Data were collected using the COVID Symptom Study in May-June 2020. Analyses investigated associations between predicted or tested COVID-19 status and menopausal status, COCP use, and HRT use, adjusting for age, smoking and BMI, with follow-up age sensitivity analysis, and validation in a subset of participants from the TwinsUK cohort. Menopausal women had higher rates of predicted COVID-19 (P = 0.003). COCP-users had lower rates of predicted COVID-19 (P = 8.03E-05), with reduction in hospital attendance (P = 0.023). Menopausal women using HRT or hormonal therapies did not exhibit consistent associations, including increased rates of predicted COVID-19 (P = 2.22E-05) for HRT users alone. The findings support a protective effect of estrogen exposure on COVID-19, based on positive association between predicted COVID-19 with menopausal status, and negative association with COCP use. HRT use was positively associated with COVID-19, but the results should be considered with caution due to lack of data on HRT type, route of administration, duration of treatment, and potential unaccounted for confounders and comorbidities.<br />Competing Interests: Zoe Global Limited co-developed the app pro bono for non-commercial purposes. JCP and JW work for Zoe Global, and TDS is a consultant to Zoe Global. IB is Chief Data Scientist Advisor for AstraZeneca. These do not alter our adherence to PLoS ONE policies on sharing data and materials.

Details

Language :
English
ISSN :
1932-6203
Volume :
16
Issue :
9
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
34506535
Full Text :
https://doi.org/10.1371/journal.pone.0257051